Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

Ib Clinical Trial of ANA598. Anadys has completed preparations required to initiate a Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from this study in the first quarter of 2009. Based on the data from the first three cohorts, Anadys may elect to explore once daily dosing and/or other dose levels of ANA598.

-- Conclusion of Healthy Volunteer Study in Phase I Clinical Trial of ANA598. In September, Anadys announced preliminary results of the Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in HCV infected patients. ANA598 was well tolerated at all doses tested, and all doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical data. Safety and PK data from all dose levels in the Phase I clinical trial of ANA598 will be presented in a late-breaker poster session on November 3 at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at AASLD in two additional poster presentations on November 4.

-- Initiation of Long-Term Chronic Toxicology Studies of ANA598. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

-- Phase I Clinical Trial of ANA773 in HCV. In July, Anadys announced that it was resuming
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... August 28, 2014 Earlier this month, ... in partnership with the U.S. Air Force on ... The results indicated that this type of fuel made ... and will be important to America’s Eco friendly future. ... has a mandate to become independent of foreign oil ...
(Date:8/27/2014)... Lake City, Utah (PRWEB) August 27, 2014 ... construction that will expand its current Salt Lake City ... currently underway outside of Utah to ultimately create 1,000 ... next 20 years. , “Utah is home to ... of whom can be credited with Varian’s success in ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that ... in its catalogue: Global Biodegradable ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable ... are readily decomposed by the action of ... packaging in terms of raw materials, production ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... Officer of Alexion,Pharmaceuticals, will present at the William ... 9:10 a.m., local time (10:10 a.m., eastern) on,Thursday, ... Mr. Sinha,s remarks will be available live. You ...
... III study, consistent with landmark IRIS trial, which established Gleevec as standard ... of care, ... molecular responses ... of Gleevec may help optimize ...
... One of the Industry,s Largest eClinical ... ... (Nasdaq: PRXL ), a leading global biopharmaceutical services,organization, today ... company traded on the London Stock Exchange, ("ClinPhone"),have reached agreement ...
Cached Biology Technology:Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 2Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 4Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 6Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 7Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 8Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 9Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 10Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 11Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 12Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 13PAREXEL Reaches Agreement To Acquire ClinPhone 2PAREXEL Reaches Agreement To Acquire ClinPhone 3PAREXEL Reaches Agreement To Acquire ClinPhone 4PAREXEL Reaches Agreement To Acquire ClinPhone 5
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... than 25 million kilometres of new roads will be ... slice into Earth,s last wildernesses, where they bring an ... , Now, an ambitious study has created a ,global ... try to balance the competing demands of development and ... ,environmental-values, layer that estimates that natural importance of ecosystems ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Japanese researchers have identified a key step in metabolic pathways ... the protein complex TORC 2 was published online in the ... activates a protein called Akt, which plays a crucial role ... of microbiology in the College of Biological Sciences at UC ...
... by Rice University bioengineers finds that the workhorse proteins that ... protein, called kinesin, is a two-legged molecular machine. Rice,s scientists ... both singly and in pairs, and they report this week ... together -- in part because they are so effective on ...
... One of the most frustrating problems faced by doctors who ... More than 38,000 people in the United States die ... are desperately needed. For almost three decades, scientists and ... is mutated in virtually all pancreatic cancers, making it an ...
Cached Biology News:Understanding diabetes at the molecular level 2'Prima donna' protein doesn't work well in pairs 2'Prima donna' protein doesn't work well in pairs 3UNC team discovers promising target for new pancreatic cancer treatments 2
... AVOID FREEZE/THAW CYCLES. An assay kit designed ... Western blotting. PARP is an enzyme implicated ... apoptosis, PARP is cleaved by caspase-3. Cleavage ... to 85 kDa is a hallmark of ...
... These handy dispensers save ... glasses, wipers, hats, and other ... benchtop storage bins for small ... and manufacturing. Clear acrylic. Many ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: